{"product_id":"human-chorionic-gonadotropinhcg-5000iu-vial","title":"Human chorionic gonadotropin(HCG) 5000iu vial","description":"\u003cp data-end=\"518\" data-start=\"68\"\u003e\u003cspan\u003e\u003cstrong\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"518\" data-start=\"68\"\u003e\u003cstrong\u003eHuman chorionic gonadotropin\u003c\/strong\u003e(HCG) a \u003cstrong data-end=\"159\" data-start=\"135\"\u003eglycoprotein hormone\u003c\/strong\u003e (α\/β subunits) that acts as a \u003cstrong data-end=\"228\" data-start=\"190\"\u003epotent LH-receptor (LHCGR) agonist\u003c\/strong\u003e. In ovaries it triggers \u003cstrong data-end=\"290\" data-start=\"253\"\u003efinal oocyte maturation\/ovulation\u003c\/strong\u003e and supports the \u003cstrong data-end=\"325\" data-start=\"308\"\u003ecorpus luteum\u003c\/strong\u003e; in testes it stimulates \u003cstrong data-end=\"382\" data-start=\"351\"\u003eLeydig cells → testosterone\u003c\/strong\u003e and, with FSH, \u003cstrong data-end=\"417\" data-start=\"398\"\u003espermatogenesis\u003c\/strong\u003e. hCG is \u003cstrong data-end=\"447\" data-start=\"426\"\u003eprescription-only\u003c\/strong\u003e; formulations include urinary-derived (u-hCG) and recombinant (r-hCG).\u003c\/p\u003e\n\u003chr data-end=\"523\" data-start=\"520\"\u003e\n\u003ch3 data-end=\"579\" data-start=\"525\"\u003eAdditional Benefits of hCG Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2752\" data-start=\"581\"\u003e\n\u003cthead data-end=\"609\" data-start=\"581\"\u003e\n\u003ctr data-end=\"609\" data-start=\"581\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"591\" data-start=\"581\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"609\" data-start=\"591\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2752\" data-start=\"620\"\u003e\n\u003ctr data-end=\"901\" data-start=\"620\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"668\" data-start=\"620\"\u003e\u003cstrong data-end=\"667\" data-start=\"622\"\u003e1 Male hypogonadotropic hypogonadism (HH)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"901\" data-start=\"668\"\u003ehCG \u003cstrong data-end=\"704\" data-start=\"674\"\u003erestores intratesticular T\u003c\/strong\u003e and supports \u003cstrong data-end=\"737\" data-start=\"718\"\u003espermatogenesis\u003c\/strong\u003e when combined with \u003cstrong data-end=\"764\" data-start=\"757\"\u003eFSH\u003c\/strong\u003e; monotherapy can normalize serum T and libido\/energy in HH while preserving fertility potential. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JCEM; Endocrine Reviews\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1193\" data-start=\"902\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"961\" data-start=\"902\"\u003e\u003cstrong data-end=\"960\" data-start=\"904\"\u003e2 Fertility preservation during testosterone therapy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1193\" data-start=\"961\"\u003eLow-dose adjunct hCG can \u003cstrong data-end=\"1018\" data-start=\"988\"\u003emaintain intratesticular T\u003c\/strong\u003e, \u003cstrong data-end=\"1041\" data-start=\"1020\"\u003etesticular volume\u003c\/strong\u003e, and \u003cstrong data-end=\"1067\" data-start=\"1047\"\u003esperm production\u003c\/strong\u003e in men receiving exogenous testosterone who wish to \u003cstrong data-end=\"1141\" data-start=\"1120\"\u003eavoid azoospermia\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Fertility and Sterility; Andrology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1438\" data-start=\"1194\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1253\" data-start=\"1194\"\u003e\u003cstrong data-end=\"1252\" data-start=\"1196\"\u003e3 Induction of spermatogenesis after AAS suppression\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1438\" data-start=\"1253\"\u003ePost–anabolic steroid or prolonged TRT, \u003cstrong data-end=\"1308\" data-start=\"1295\"\u003ehCG ± FSH\u003c\/strong\u003e protocols help \u003cstrong data-end=\"1355\" data-start=\"1324\"\u003ere-initiate spermatogenesis\u003c\/strong\u003e over months. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Human Reproduction; Translational Andrology \u0026amp; Urology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1645\" data-start=\"1439\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1489\" data-start=\"1439\"\u003e\u003cstrong data-end=\"1488\" data-start=\"1441\"\u003e4 Prepubertal cryptorchidism (select cases)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1645\" data-start=\"1489\"\u003ehCG can promote \u003cstrong data-end=\"1529\" data-start=\"1507\"\u003etesticular descent\u003c\/strong\u003e in some boys (variable success); surgical orchiopexy remains standard. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Pediatrics; European Urology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1887\" data-start=\"1646\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1673\" data-start=\"1646\"\u003e\u003cstrong data-end=\"1672\" data-start=\"1648\"\u003e5 Female ART trigger\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1887\" data-start=\"1673\"\u003eIn IVF, r-hCG\/u-hCG reliably \u003cstrong data-end=\"1740\" data-start=\"1704\"\u003etriggers final oocyte maturation\u003c\/strong\u003e; \u003cstrong data-end=\"1772\" data-start=\"1742\"\u003ekisspeptin or GnRH agonist\u003c\/strong\u003emay be used in high-OHSS-risk patients. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Human Reproduction Update; Reproductive Biomedicine Online\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2085\" data-start=\"1888\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1921\" data-start=\"1888\"\u003e\u003cstrong data-end=\"1920\" data-start=\"1890\"\u003e6 Luteal support (adjunct)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2085\" data-start=\"1921\"\u003ehCG can support early luteal progesterone production; modern programs often prefer \u003cstrong data-end=\"2022\" data-start=\"2006\"\u003eprogesterone\u003c\/strong\u003e to reduce \u003cstrong data-end=\"2041\" data-start=\"2033\"\u003eOHSS\u003c\/strong\u003e risk. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;F\u0026amp;S Reviews; Cochrane\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2329\" data-start=\"2086\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2129\" data-start=\"2086\"\u003e\u003cstrong data-end=\"2128\" data-start=\"2088\"\u003e7 Hypogonadism with fertility intent\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2329\" data-start=\"2129\"\u003eIn functional\/secondary hypogonadism (obesity, opioids), hCG can \u003cstrong data-end=\"2207\" data-start=\"2196\"\u003eraise T\u003c\/strong\u003e while \u003cstrong data-end=\"2237\" data-start=\"2214\"\u003eretaining fertility\u003c\/strong\u003e, sometimes avoiding TRT. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Frontiers in Endocrinology; Clinical Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2548\" data-start=\"2330\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2354\" data-start=\"2330\"\u003e\u003cstrong data-end=\"2353\" data-start=\"2332\"\u003e8 Diagnostic uses\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2548\" data-start=\"2354\"\u003e\n\u003cstrong data-end=\"2381\" data-start=\"2356\"\u003ehCG stimulation tests\u003c\/strong\u003e assess \u003cstrong data-end=\"2412\" data-start=\"2389\"\u003eLeydig cell reserve\u003c\/strong\u003e or \u003cstrong data-end=\"2435\" data-start=\"2416\"\u003esteroidogenesis\u003c\/strong\u003e in ambiguous genitalia\/CAH workups. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Best Practice \u0026amp; Research Clinical Endocrinology \u0026amp; Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2752\" data-start=\"2549\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2572\" data-start=\"2549\"\u003e\u003cstrong data-end=\"2571\" data-start=\"2551\"\u003e9 Onco-fertility\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2752\" data-start=\"2572\"\u003eIn men treated for pituitary\/cranial tumors, hCG±FSH helps \u003cstrong data-end=\"2659\" data-start=\"2633\"\u003ere-establish fertility\u003c\/strong\u003e when gonadotropins recover poorly. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Annals of Oncology; Endocrine Connections\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2757\" data-start=\"2754\"\u003e\n\u003ch2 data-end=\"2794\" data-start=\"2759\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"2831\" data-start=\"2796\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3200\" data-start=\"2832\"\u003e\n\u003cli data-end=\"2947\" data-start=\"2832\"\u003e\n\u003cp data-end=\"2947\" data-start=\"2834\"\u003e\u003cstrong data-end=\"2858\" data-start=\"2834\"\u003eLHCGR (GPCR) agonist\u003c\/strong\u003e → \u003cstrong data-end=\"2878\" data-start=\"2861\"\u003eGs → cAMP\/PKA\u003c\/strong\u003e → \u003cstrong data-end=\"2900\" data-start=\"2881\"\u003esteroidogenesis\u003c\/strong\u003e (↑ StAR, CYP11A1) and \u003cstrong data-end=\"2944\" data-start=\"2923\"\u003egamete maturation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3086\" data-start=\"2948\"\u003e\n\u003cp data-end=\"3086\" data-start=\"2950\"\u003e\u003cstrong data-end=\"2964\" data-start=\"2950\"\u003eIn testes:\u003c\/strong\u003e Leydig cells → \u003cstrong data-end=\"2996\" data-start=\"2980\"\u003etestosterone\u003c\/strong\u003e; Sertoli support via paracrine crosstalk (FSH still required for full spermatogenesis).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3200\" data-start=\"3087\"\u003e\n\u003cp data-end=\"3200\" data-start=\"3089\"\u003e\u003cstrong data-end=\"3104\" data-start=\"3089\"\u003eIn ovaries:\u003c\/strong\u003e The “LH surge mimic” for \u003cstrong data-end=\"3151\" data-start=\"3130\"\u003eoocyte maturation\u003c\/strong\u003e, \u003cstrong data-end=\"3170\" data-start=\"3153\"\u003eluteinization\u003c\/strong\u003e, and \u003cstrong data-end=\"3192\" data-start=\"3176\"\u003eprogesterone\u003c\/strong\u003e output.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3229\" data-start=\"3202\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3529\" data-start=\"3231\"\u003e\n\u003cthead data-end=\"3273\" data-start=\"3231\"\u003e\n\u003ctr data-end=\"3273\" data-start=\"3231\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3241\" data-start=\"3231\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3262\" data-start=\"3241\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3273\" data-start=\"3262\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3529\" data-start=\"3288\"\u003e\n\u003ctr data-end=\"3370\" data-start=\"3288\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3318\" data-start=\"3288\"\u003ecAMP\/PKA → StAR\/CYP enzymes\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3352\" data-start=\"3318\"\u003e↑ Testosterone \/ ↑ Progesterone\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3370\" data-start=\"3352\"\u003eTestis \/ Ovary\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3448\" data-start=\"3371\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3399\" data-start=\"3371\"\u003eParacrine Sertoli support\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3438\" data-start=\"3399\"\u003eSpermatogenic progression (with FSH)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3448\" data-start=\"3438\"\u003eTestis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3529\" data-start=\"3449\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3488\" data-start=\"3449\"\u003eCumulus expansion\/meiotic resumption\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3514\" data-start=\"3488\"\u003eFinal oocyte maturation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3529\" data-start=\"3514\"\u003eART trigger\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3534\" data-start=\"3531\"\u003e\n\u003ch2 data-end=\"3558\" data-start=\"3536\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"3817\" data-start=\"3560\"\u003e\n\u003cli data-end=\"3588\" data-start=\"3560\"\u003e\n\u003cp data-end=\"3588\" data-start=\"3562\"\u003e\u003cstrong data-end=\"3572\" data-start=\"3562\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-end=\"3585\" data-start=\"3573\"\u003eSC or IM\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3719\" data-start=\"3589\"\u003e\n\u003cp data-end=\"3719\" data-start=\"3591\"\u003e\u003cstrong data-end=\"3605\" data-start=\"3591\"\u003eHalf-life:\u003c\/strong\u003e u-hCG \u003cstrong data-end=\"3624\" data-start=\"3612\"\u003e~24–36 h\u003c\/strong\u003e; r-hCG similar, enabling once-every-1–3-day dosing (men) or single \u003cstrong data-end=\"3703\" data-start=\"3692\"\u003etrigger\u003c\/strong\u003e dose (women).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3817\" data-start=\"3720\"\u003e\n\u003cp data-end=\"3817\" data-start=\"3722\"\u003e\u003cstrong data-end=\"3736\" data-start=\"3722\"\u003eDetection:\u003c\/strong\u003e Prolonged biologic activity; relevant for \u003cstrong data-end=\"3794\" data-start=\"3779\"\u003eanti-doping\u003c\/strong\u003e (detectable for days).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"3822\" data-start=\"3819\"\u003e\n\u003ch2 data-end=\"3864\" data-start=\"3824\"\u003e4. Pre-clinical and Clinical Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"3895\" data-start=\"3866\"\u003e4.1 Male HH \u0026amp; Fertility\u003c\/h3\u003e\n\u003cp data-end=\"4113\" data-start=\"3896\"\u003eSequential \u003cstrong data-end=\"3921\" data-start=\"3907\"\u003ehCG → +FSH\u003c\/strong\u003e regimens restore \u003cstrong data-end=\"3944\" data-start=\"3939\"\u003eT\u003c\/strong\u003e, \u003cstrong data-end=\"3967\" data-start=\"3946\"\u003etesticular volume\u003c\/strong\u003e, and \u003cstrong data-end=\"3989\" data-start=\"3973\"\u003esperm counts\u003c\/strong\u003e; pregnancy rates improve over \u003cstrong data-end=\"4035\" data-start=\"4020\"\u003e6–18 months\u003c\/strong\u003e depending on baseline testicular size, cryptorchidism history, and adherence.\u003c\/p\u003e\n\u003ch3 data-end=\"4154\" data-start=\"4115\"\u003e4.2 Men on TRT desiring fertility\u003c\/h3\u003e\n\u003cp data-end=\"4287\" data-start=\"4155\"\u003eAdjunct \u003cstrong data-end=\"4179\" data-start=\"4163\"\u003elow-dose hCG\u003c\/strong\u003e maintains \u003cstrong data-end=\"4211\" data-start=\"4190\"\u003eintratesticular T\u003c\/strong\u003e and mitigates \u003cstrong data-end=\"4248\" data-start=\"4226\"\u003etesticular atrophy\u003c\/strong\u003e; if azoospermic, add \u003cstrong data-end=\"4277\" data-start=\"4270\"\u003eFSH\u003c\/strong\u003e and time.\u003c\/p\u003e\n\u003ch3 data-end=\"4309\" data-start=\"4289\"\u003e4.3 Female ART\u003c\/h3\u003e\n\u003cp data-end=\"4466\" data-start=\"4310\"\u003er-hCG is a gold-standard \u003cstrong data-end=\"4346\" data-start=\"4335\"\u003etrigger\u003c\/strong\u003e; however, \u003cstrong data-end=\"4370\" data-start=\"4357\"\u003eOHSS risk\u003c\/strong\u003e rises in high responders—\u003cstrong data-end=\"4420\" data-start=\"4396\"\u003eGnRH-agonist trigger\u003c\/strong\u003e or \u003cstrong data-end=\"4438\" data-start=\"4424\"\u003ekisspeptin\u003c\/strong\u003emay be safer in such cases.\u003c\/p\u003e\n\u003cblockquote data-end=\"4683\" data-start=\"4468\"\u003e\n\u003cp data-end=\"4683\" data-start=\"4470\"\u003e\u003cstrong data-end=\"4496\" data-start=\"4470\"\u003eEvidence quality note:\u003c\/strong\u003e Strong, guideline-level support for \u003cstrong data-end=\"4539\" data-start=\"4533\"\u003eHH\u003c\/strong\u003e, \u003cstrong data-end=\"4556\" data-start=\"4541\"\u003eART trigger\u003c\/strong\u003e, and \u003cstrong data-end=\"4588\" data-start=\"4562\"\u003efertility preservation\u003c\/strong\u003e; variable\/limited utility for cryptorchidism and functional hypogonadism depends on phenotype.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"4688\" data-start=\"4685\"\u003e\n\u003ch2 data-end=\"4723\" data-start=\"4690\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5171\" data-start=\"4725\"\u003e\n\u003cthead data-end=\"4755\" data-start=\"4725\"\u003e\n\u003ctr data-end=\"4755\" data-start=\"4725\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"4733\" data-start=\"4725\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"4745\" data-start=\"4733\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"4755\" data-start=\"4745\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5171\" data-start=\"4770\"\u003e\n\u003ctr data-end=\"4870\" data-start=\"4770\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4811\" data-start=\"4770\"\u003e\u003cstrong data-end=\"4810\" data-start=\"4772\"\u003eOpioid-induced androgen deficiency\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4853\" data-start=\"4811\"\u003ePreserve fertility, raise T without TRT\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4870\" data-start=\"4853\"\u003eSmall studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4975\" data-start=\"4871\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4916\" data-start=\"4871\"\u003e\u003cstrong data-end=\"4915\" data-start=\"4873\"\u003eObesity-related secondary hypogonadism\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4960\" data-start=\"4916\"\u003eLHCGR drive with lifestyle\/GLP-1 adjuncts\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4975\" data-start=\"4960\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5090\" data-start=\"4976\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5040\" data-start=\"4976\"\u003e\u003cstrong data-end=\"5039\" data-start=\"4978\"\u003eFemale hypoactive sexual desire (hCG-progesterone milieu)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5076\" data-start=\"5040\"\u003eHormonal orchestration hypotheses\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5090\" data-start=\"5076\"\u003eVery early\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5171\" data-start=\"5091\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5121\" data-start=\"5091\"\u003e\u003cstrong data-end=\"5120\" data-start=\"5093\"\u003ehCG micro-dosing in ART\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5150\" data-start=\"5121\"\u003eFine-tuning luteal support\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5171\" data-start=\"5150\"\u003eProgram-dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5176\" data-start=\"5173\"\u003e\n\u003ch2 data-end=\"5207\" data-start=\"5178\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6155\" data-start=\"5209\"\u003e\n\u003cli data-end=\"5359\" data-start=\"5209\"\u003e\n\u003cp data-end=\"5359\" data-start=\"5211\"\u003e\u003cstrong data-end=\"5222\" data-start=\"5211\"\u003eCommon:\u003c\/strong\u003e Injection-site pain, \u003cstrong data-end=\"5256\" data-start=\"5244\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-end=\"5275\" data-start=\"5258\"\u003emood lability\u003c\/strong\u003e, \u003cstrong data-end=\"5288\" data-start=\"5277\"\u003efatigue\u003c\/strong\u003e, \u003cstrong data-end=\"5307\" data-start=\"5290\"\u003eacne\/oiliness\u003c\/strong\u003e (from ↑ androgens in men), \u003cstrong data-end=\"5356\" data-start=\"5335\"\u003ebreast tenderness\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5516\" data-start=\"5360\"\u003e\n\u003cp data-end=\"5516\" data-start=\"5362\"\u003e\u003cstrong data-end=\"5370\" data-start=\"5362\"\u003eMen:\u003c\/strong\u003e \u003cstrong data-end=\"5387\" data-start=\"5371\"\u003eGynecomastia\u003c\/strong\u003e (via aromatization), \u003cstrong data-end=\"5427\" data-start=\"5409\"\u003eerythrocytosis\u003c\/strong\u003e (rare vs TRT), \u003cstrong data-end=\"5460\" data-start=\"5443\"\u003eworsening OSA\u003c\/strong\u003e in predisposed, \u003cstrong data-end=\"5496\" data-start=\"5477\"\u003etesticular ache\u003c\/strong\u003e early in therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5678\" data-start=\"5517\"\u003e\n\u003cp data-end=\"5678\" data-start=\"5519\"\u003e\u003cstrong data-end=\"5529\" data-start=\"5519\"\u003eWomen:\u003c\/strong\u003e \u003cstrong data-end=\"5574\" data-start=\"5530\"\u003eOvarian hyperstimulation syndrome (OHSS)\u003c\/strong\u003e risk post-trigger (ascites, hemoconcentration), \u003cstrong data-end=\"5645\" data-start=\"5623\"\u003emultiple gestation\u003c\/strong\u003e risk if not carefully managed.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5757\" data-start=\"5679\"\u003e\n\u003cp data-end=\"5757\" data-start=\"5681\"\u003e\u003cstrong data-end=\"5702\" data-start=\"5681\"\u003eCardio-metabolic:\u003c\/strong\u003e Monitor \u003cstrong data-end=\"5734\" data-start=\"5711\"\u003eBP, lipids, glucose\u003c\/strong\u003e when androgens rise.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5811\" data-start=\"5758\"\u003e\n\u003cp data-end=\"5811\" data-start=\"5760\"\u003e\u003cstrong data-end=\"5770\" data-start=\"5760\"\u003ePsych:\u003c\/strong\u003e Mood changes\/irritability in a subset.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5974\" data-start=\"5812\"\u003e\n\u003cp data-end=\"5974\" data-start=\"5814\"\u003e\u003cstrong data-end=\"5836\" data-start=\"5814\"\u003eContraindications:\u003c\/strong\u003e \u003cstrong data-end=\"5866\" data-start=\"5837\"\u003eHormone-sensitive cancers\u003c\/strong\u003e, pregnancy (outside ART indication), active \u003cstrong data-end=\"5937\" data-start=\"5911\"\u003ethromboembolic disease\u003c\/strong\u003e, uncontrolled endocrine disorders.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6155\" data-start=\"5975\"\u003e\n\u003cp data-end=\"6155\" data-start=\"5977\"\u003e\u003cstrong data-end=\"5999\" data-start=\"5977\"\u003eDrug interactions:\u003c\/strong\u003e Additive androgenic effects with \u003cstrong data-end=\"6044\" data-start=\"6033\"\u003eAAS\/TRT\u003c\/strong\u003e; \u003cstrong data-end=\"6076\" data-start=\"6046\"\u003earomatase inhibitors\/SERMs\u003c\/strong\u003e sometimes co-used to manage estradiol\/gynecomastia in men aiming at fertility.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6186\" data-start=\"6157\"\u003e\u003cstrong data-end=\"6186\" data-start=\"6157\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6772\" data-start=\"6188\"\u003e\n\u003cthead data-end=\"6275\" data-start=\"6188\"\u003e\n\u003ctr data-end=\"6275\" data-start=\"6188\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6198\" data-start=\"6188\"\u003eFeature\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6208\" data-start=\"6198\"\u003e\u003cstrong data-end=\"6207\" data-start=\"6200\"\u003ehCG\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6233\" data-start=\"6208\"\u003e\u003cstrong data-end=\"6232\" data-start=\"6210\"\u003eTestosterone (TRT)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6255\" data-start=\"6233\"\u003e\u003cstrong data-end=\"6254\" data-start=\"6235\"\u003eFSH (uFSH\/rFSH)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6275\" data-start=\"6255\"\u003e\u003cstrong data-end=\"6273\" data-start=\"6257\"\u003eGnRH agonist\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6772\" data-start=\"6298\"\u003e\n\u003ctr data-end=\"6452\" data-start=\"6298\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6338\" data-start=\"6298\"\u003eFertility while treating hypogonadism\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6354\" data-start=\"6338\"\u003e\u003cstrong data-end=\"6353\" data-start=\"6340\"\u003ePreserved\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6390\" data-start=\"6354\"\u003e\n\u003cstrong data-end=\"6370\" data-start=\"6356\"\u003eSuppresses\u003c\/strong\u003e(azoospermia risk)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6421\" data-start=\"6390\"\u003e\u003cstrong data-end=\"6420\" data-start=\"6392\"\u003eSupports spermatogenesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6452\" data-start=\"6421\"\u003eStimulates axis (if intact)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6550\" data-start=\"6453\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6470\" data-start=\"6453\"\u003ePrimary target\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6488\" data-start=\"6470\"\u003e\u003cstrong data-end=\"6487\" data-start=\"6472\"\u003eLH receptor\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6508\" data-start=\"6488\"\u003eAndrogen receptor\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6523\" data-start=\"6508\"\u003eFSH receptor\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6550\" data-start=\"6523\"\u003ePituitary GnRH receptor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6673\" data-start=\"6551\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6562\" data-start=\"6551\"\u003eKey risk\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6596\" data-start=\"6562\"\u003e\u003cstrong data-end=\"6595\" data-start=\"6564\"\u003eGynecomastia \/ OHSS (women)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6626\" data-start=\"6596\"\u003eErythrocytosis, infertility\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6645\" data-start=\"6626\"\u003eCost, injections\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6673\" data-start=\"6645\"\u003eFlare, hypoestrogenic sx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6772\" data-start=\"6674\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6687\" data-start=\"6674\"\u003eUse in ART\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6718\" data-start=\"6687\"\u003e\u003cstrong data-end=\"6717\" data-start=\"6689\"\u003eTrigger \/ luteal support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6723\" data-start=\"6718\"\u003eNo\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6745\" data-start=\"6723\"\u003eOvarian stimulation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6772\" data-start=\"6745\"\u003eTrigger (alt), down-reg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6777\" data-start=\"6774\"\u003e\n\u003ch2 data-end=\"6819\" data-start=\"6779\"\u003e7. Regulatory \u0026amp; Anti-Doping Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7229\" data-start=\"6821\"\u003e\n\u003cli data-end=\"6959\" data-start=\"6821\"\u003e\n\u003cp data-end=\"6959\" data-start=\"6823\"\u003e\u003cstrong data-end=\"6837\" data-start=\"6823\"\u003eApprovals:\u003c\/strong\u003e Widely approved for \u003cstrong data-end=\"6869\" data-start=\"6858\"\u003emale HH\u003c\/strong\u003e, \u003cstrong data-end=\"6909\" data-start=\"6871\"\u003einduction of ovulation\/ART trigger\u003c\/strong\u003e, and \u003cstrong data-end=\"6933\" data-start=\"6915\"\u003ecryptorchidism\u003c\/strong\u003e (regional differences).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7105\" data-start=\"6960\"\u003e\n\u003cp data-end=\"7105\" data-start=\"6962\"\u003e\u003cstrong data-end=\"6986\" data-start=\"6962\"\u003eWeight-loss warning:\u003c\/strong\u003e The \u003cstrong data-end=\"7005\" data-start=\"6991\"\u003e“hCG diet”\u003c\/strong\u003e has been \u003cstrong data-end=\"7030\" data-start=\"7015\"\u003ediscredited\u003c\/strong\u003e; FDA\/FTC warn against hCG for weight loss—no efficacy, unnecessary risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7229\" data-start=\"7106\"\u003e\n\u003cp data-end=\"7229\" data-start=\"7108\"\u003e\u003cstrong data-end=\"7118\" data-start=\"7108\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-end=\"7150\" data-start=\"7119\"\u003eProhibited by WADA in males\u003c\/strong\u003e (can mask or restore T after AAS) and is \u003cstrong data-end=\"7206\" data-start=\"7192\"\u003edetectable\u003c\/strong\u003e; sanctions are common.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7234\" data-start=\"7231\"\u003e\n\u003ch2 data-end=\"7259\" data-start=\"7236\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"7788\" data-start=\"7261\"\u003e\n\u003cli data-end=\"7412\" data-start=\"7261\"\u003e\n\u003cp data-end=\"7412\" data-start=\"7263\"\u003e\u003cstrong data-end=\"7305\" data-start=\"7263\"\u003ePersonalized male fertility protocols:\u003c\/strong\u003e Optimizing \u003cstrong data-end=\"7328\" data-start=\"7317\"\u003ehCG+FSH\u003c\/strong\u003e schedules by \u003cstrong data-end=\"7372\" data-start=\"7342\"\u003ebaseline testicular volume\u003c\/strong\u003e, \u003cstrong data-end=\"7391\" data-start=\"7374\"\u003eAMH\/inhibin B\u003c\/strong\u003e, and \u003cstrong data-end=\"7409\" data-start=\"7397\"\u003egenetics\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7573\" data-start=\"7413\"\u003e\n\u003cp data-end=\"7573\" data-start=\"7415\"\u003e\u003cstrong data-end=\"7443\" data-start=\"7415\"\u003eAdjuncts to reduce OHSS:\u003c\/strong\u003e Wider adoption of \u003cstrong data-end=\"7498\" data-start=\"7462\"\u003eGnRH-agonist\/kisspeptin triggers\u003c\/strong\u003e and tailored luteal support instead of high-dose hCG in high responders.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7687\" data-start=\"7574\"\u003e\n\u003cp data-end=\"7687\" data-start=\"7576\"\u003e\u003cstrong data-end=\"7611\" data-start=\"7576\"\u003eFunctional hypogonadism trials:\u003c\/strong\u003e Head-to-head \u003cstrong data-end=\"7639\" data-start=\"7625\"\u003ehCG vs TRT\u003c\/strong\u003e (QoL, metabolic outcomes, fertility metrics).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7788\" data-start=\"7688\"\u003e\n\u003cp data-end=\"7788\" data-start=\"7690\"\u003e\u003cstrong data-end=\"7711\" data-start=\"7690\"\u003eLong-acting r-hCG\u003c\/strong\u003e and \u003cstrong data-end=\"7733\" data-start=\"7716\"\u003eself-injector\u003c\/strong\u003e devices to improve adherence and cost-effectiveness.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7793\" data-start=\"7790\"\u003e\n\u003ch3 data-end=\"7818\" data-start=\"7795\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"8670\" data-start=\"7820\"\u003e\n\u003cli data-end=\"7977\" data-start=\"7820\"\u003e\n\u003cp data-end=\"7977\" data-start=\"7822\"\u003e\u003cstrong data-end=\"7891\" data-start=\"7822\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism; Endocrine Reviews\u003c\/strong\u003e — Diagnosis\/management of male hypogonadism and use of \u003cstrong data-end=\"7960\" data-start=\"7947\"\u003ehCG ± FSH\u003c\/strong\u003e for fertility.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8122\" data-start=\"7978\"\u003e\n\u003cp data-end=\"8122\" data-start=\"7980\"\u003e\u003cstrong data-end=\"8034\" data-start=\"7980\"\u003eFertility and Sterility; Human Reproduction Update\u003c\/strong\u003e — \u003cstrong data-end=\"8052\" data-start=\"8037\"\u003eIVF trigger\u003c\/strong\u003e strategies (hCG vs GnRH-agonist vs kisspeptin) and OHSS mitigation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8240\" data-start=\"8123\"\u003e\n\u003cp data-end=\"8240\" data-start=\"8125\"\u003e\u003cstrong data-end=\"8158\" data-start=\"8125\"\u003eAndrology; Human Reproduction\u003c\/strong\u003e — \u003cstrong data-end=\"8198\" data-start=\"8161\"\u003eFertility preservation during TRT\u003c\/strong\u003e using low-dose hCG; recovery after AAS.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8340\" data-start=\"8241\"\u003e\n\u003cp data-end=\"8340\" data-start=\"8243\"\u003e\u003cstrong data-end=\"8275\" data-start=\"8243\"\u003ePediatrics; European Urology\u003c\/strong\u003e — \u003cstrong data-end=\"8296\" data-start=\"8278\"\u003eCryptorchidism\u003c\/strong\u003e medical therapy evidence and limitations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8472\" data-start=\"8341\"\u003e\n\u003cp data-end=\"8472\" data-start=\"8343\"\u003e\u003cstrong data-end=\"8393\" data-start=\"8343\"\u003eBest Practice \u0026amp; Research Clin Endocrinol Metab\u003c\/strong\u003e — \u003cstrong data-end=\"8421\" data-start=\"8396\"\u003ehCG stimulation tests\u003c\/strong\u003e in disorders of sex development\/steroidogenesis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8575\" data-start=\"8473\"\u003e\n\u003cp data-end=\"8575\" data-start=\"8475\"\u003e\u003cstrong data-end=\"8503\" data-start=\"8475\"\u003eFDA\/FTC notices; Obesity\u003c\/strong\u003e — Warnings against the \u003cstrong data-end=\"8539\" data-start=\"8527\"\u003ehCG diet\u003c\/strong\u003e and lack of weight-loss efficacy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8670\" data-start=\"8576\"\u003e\n\u003cp data-end=\"8670\" data-start=\"8578\"\u003e\u003cstrong data-end=\"8612\" data-start=\"8578\"\u003eWADA \/ Drug Testing \u0026amp; Analysis\u003c\/strong\u003e — Prohibited status, detection methods, and case report\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684851446098,"sku":null,"price":32.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/HCG_5000iu.png?v=1770834846","url":"https:\/\/sciencepeptideslab.com\/products\/human-chorionic-gonadotropinhcg-5000iu-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}